GeoVax Labs, Inc. Provides Clinical Stud... (ne responses. Stimulation of both T cell...)

GeoVax Labs, Inc. Provides Clinical Studies Update

Date:8/5/2009

ne responses. Stimulation of both T cells and antibodies differentiates the GeoVax vaccine from many other vaccine candidates. GeoVax's DNA and MVA vaccines are used in a prime-boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. These particles contain proteins that mimic more than half of the components of the AIDS virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective antibody response against the natural form of the virus envelope glycoprotein as well as protective T cells.

"Vaccine trials can be a slow process," said Harriet Robinson, Ph.D., developer of the vaccine and Senior V.P. of Research and Development. "The therapeutic trials should move more rapidly than the preventative trials because each participant provides not only endpoints for safety and immunogenicity, but also an endpoint for protective efficacy. But, before these trials can scale up, we need to demonstrate safety for our participants in both vaccination and subsequent phases of therapeutic studies. We have safety and efficacy data for non-human primates. The next step is determining safety in a small trial of intensively monitored humans."

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. GeoVax Labs, Inc. Announces Resignation of Director
2. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
3. GeoVax to Exhibit at the 2009 BIO International Convention
4. GeoVax Labs, Inc. Announces First Quarter Financial Results
5. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
6. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax to Present at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
10. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference

Post Your Comments:

GeoVax Labs, Inc. Provides Clinical Stud...(ne responses. Stimulation of both T cell...)